BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
USDÂ 10,93
arrow_downward
-1,00%(-0,11) 1D
28 Aug., 16:00:00 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNRY...
Open
USDÂ 11,08
High
USDÂ 11,08
Low
USDÂ 10,93
Mkt. cap
2,64Â mjd
Avg. vol.
2,57Â k
Volume
2,01Â k
P/E ratio
11,28
52-wk high
USDÂ 13,00
52-wk low
USDÂ 8,67
EPS
USDÂ 0,97
Beta
1,40
Shares outstanding
237,73Â m
No. of employees
2Â k
Open
USDÂ 11,08
High
USDÂ 11,08
Low
USDÂ 10,93
Mkt. cap
2,64Â mjd
Avg. vol.
2,57Â k
Volume
2,01Â k
P/E ratio
11,28
52-wk high
USDÂ 13,00
52-wk low
USDÂ 8,67
EPS
USDÂ 0,97
Beta
1,40
Shares outstanding
237,73Â m
No. of employees
2Â k
News stories
From web sources and news partners
TipRanks
·
23 uur gelede
Bavarian Nordic Earnings Call Signals Profitable Growth
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination. In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S - ADR
AI content may include mistakes. Learn more